Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-832-8175
Email:info@felixvet.com
Felixvet Announces New Hires to Lead Sales
Kansas City, Mo. — March 18, 2025 — Felixvet, Inc., an Ireland-based generic companion animal pharmaceutical manufacturer, established its North American headquarters in Kansas City, Mo., in 2023, is pleased to announce the addition of Matthew Maggio and Michael Morelli as Directors of Corporate Accounts for North America. In their new roles, Maggio and Morelli will execute strategic sales plans, foster long-term partnerships, collaborate with distributor partners and drive business growth through creative marketing solutions.
Matthew Maggio has nearly two decades of experience leading high-performing teams in the pharmaceutical industry, including MWI Animal Health, Elanco and Boehringer Ingelheim Vetmedica, Inc.
Before joining Felixvet, Maggio launched his career in sales and quickly rose through the ranks to become a top-producing salesperson and account manager. Throughout his career, he has consistently excelled in competitive markets, leveraging his extensive technical knowledge in animal immunology, pharmaceuticals and product marketing to drive success.
Michael Morelli brings a wealth of experience, having previously served as a National Account Manager and Sales Director, where he successfully drove large-scale account growth and managed high-performing teams. Morelli has honed his leadership and strategic sales skills, overseen regional operations and cultivating strong customer relationships.
Before joining Felixvet, Morelli held leadership roles at Terumo Medical Corporation, IQVIA and Takeda Pharmaceuticals North America, where he successfully developed and motivated high-performing teams. Throughout his career, he has worked closely with animal health distributors and veterinarians, forging strategic partnerships to drive business growth and innovation.
“We are very pleased to have both Matthew Maggio and Michael Morelli join the team at Felixvet. Together, they bring over 40 years of experience in pharmaceutical industry sales and have a proven track record of success,” said Vince Palasota, President of Felixvet North America. “Their expertise will be instrumental in helping us achieve our growth objectives. With a wealth of experience in sales management and team leadership, they will help us on our mission to advance veterinary care by offering straight generics, value-added products, and novel solutions.”
For more information, visit Felixvet.com or info@felixvet.com.
About Felixvet:
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bio-equivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in the North American markets, upon approval by the Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.